Unipharma Co., Ltd. (6621) Stock Statistics & Valuation Metrics
Total Valuation
Unipharma Co., Ltd. has a market cap or net worth of TWD 426.01M. The enterprise value is ―.
- Market Cap
- TWD 426.01M
- Enterprise Value
- ―
Share Statistics
Unipharma Co., Ltd. has 35,501,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 35,501,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Unipharma Co., Ltd.’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -18.33%.
- Return on Equity (ROE)
- -0.18
- Return on Assets (ROA)
- -0.15
- Return on Invested Capital (ROIC)
- -18.33%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 2.60M
- Profits Per Employee
- -1.19M
- Employee Count
- 34
- Asset Turnover
- 0.32
- Inventory Turnover
- 1.51
Valuation Ratios
The current PE Ratio of Unipharma Co., Ltd. is -10.80. Unipharma Co., Ltd.’s PEG ratio is 2.88.
- PE Ratio
- -10.80
- PS Ratio
- 5.16
- PB Ratio
- 2.20
- Price to FCF
- -12.38
- Price to Operating Cash Flow
- -12.80
- PEG Ratio
- 2.88
Income Statement
In the last 12 months, Unipharma Co., Ltd. had revenue of 88.44M and earned -40.54M in profits. Earnings per share was -1.14.
- Revenue
- 88.44M
- Gross Profit
- 41.15M
- Operating Income
- -44.13M
- Pretax Income
- -40.54M
- Net Income
- -40.54M
- EBITDA
- -37.13M
- Earnings Per Share (EPS)
- -1.14
Cash Flow
In the last 12 months, operating cash flow was -33.83M and capital expenditures -1.16M, giving a free cash flow of -34.99M billion.
- Operating Cash Flow
- -33.83M
- Free Cash Flow
- -34.99M
- Free Cash Flow per Share
- -0.99
Dividends & Yields
Unipharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.21%
- Earnings Yield
- -9.41%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- -2.44%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 48.23
- Average Volume (3m)
- 58.50K
Financial Position
Unipharma Co., Ltd. as a current ratio of 4.86, with Debt / Equity ratio of 4.78%
- Current Ratio
- 4.86
- Quick Ratio
- 4.04
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- -445.71
Taxes
In the past 12 months, Unipharma Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Unipharma Co., Ltd. EV to EBITDA ratio is -11.10, with an EV/FCF ratio of -11.95.
- EV to Sales
- 4.99
- EV to EBITDA
- -11.10
- EV to Free Cash Flow
- -11.95
- EV to Operating Cash Flow
- -12.36
Balance Sheet
Unipharma Co., Ltd. has TWD 107.59M in cash and marketable securities with TWD 12.33M in debt, giving a net cash position of TWD 95.26M billion.
- Cash & Marketable Securities
- TWD 107.59M
- Total Debt
- TWD 12.33M
- Net Cash
- TWD 95.26M
- Net Cash Per Share
- TWD 2.68
- Tangible Book Value Per Share
- TWD 5.45
Margins
Gross margin is 50.03%, with operating margin of -54.60%, and net profit margin of -47.80%.
- Gross Margin
- 50.03%
- Operating Margin
- -54.60%
- Pretax Margin
- -47.80%
- Net Profit Margin
- -47.80%
- EBITDA Margin
- -44.92%
- EBIT Margin
- -54.60%
Analyst Forecast
The average price target for Unipharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -7.61%
- EPS Growth Forecast
- -3.25%
